Management of Anaplastic Large Cell Lymphoma.
Abstract Anaplastic large cell lymphoma (ALCL) is one of the most common peripheral T-cell lymphomas, and the incidence is higher in blacks than non-Hispanic whites. ALK-positive and ALK-negative ALCL are distinct subtypes that have different characteristics and clinical outcomes. Breast implant-associated ALCL is a rare lymphoma that has a good survival outcome, and a recent study showed that total capsulectomy is essential for treatment. Brentuximab vedotin (BV) is a standard treatment for relapsed/refractory ALCL. The response rate is high at 80-90%; however, once the disease progresses in patients on BV, survi...
Source: Clinical Lymphoma and Myeloma - March 29, 2017 Category: Cancer & Oncology Authors: Chihara D, Fanale MA Tags: Hematol Oncol Clin North Am Source Type: research

What Are the Functional Results and Complications With Long Stem Hemiarthroplasty in Patients With Metastases to the Proximal Femur?
CONCLUSIONS: Long stem cemented hemiarthroplasty results in fair levels of function in a complex population of patients whose prognosis is sometimes measured only in months and who otherwise might be disabled by their metastatic lesions. Comparative trials applying consistent indications and inclusion criteria should be performed between this approach and fixation with intramedullary nailing supplemented with polymethylmethacrylate as well as osteosynthesis with a plate-screw construct and polymethylmethacrylate. LEVEL OF EVIDENCE: Level IV, therapeutic study. PMID: 27052019 [PubMed - indexed for MEDLINE] (Source...
Source: Clinical Lymphoma and Myeloma - March 1, 2017 Category: Cancer & Oncology Authors: Peterson JR, Decilveo AP, O'Connor IT, Golub I, Wittig JC Tags: Clin Orthop Relat Res Source Type: research

Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.
CONCLUSIONS: The distinction between plasmablastic lymphoma from plasmablastic myeloma warrants detailed knowledge of clinical, radiological and laboratorial findings. New studies identifying distinctive phenotypical or genetic features are needed to improve the histopathological differentiation of plasmablastic neoplasms. PMID: 28249941 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 1, 2017 Category: Cancer & Oncology Authors: Ahn JS, Okal R, Vos JA, Smolkin M, Kanate AS, Rosado FG Tags: J Clin Pathol Source Type: research

Proteasome inhibitors in cancer therapy.
Abstract The ubiquitin proteasome pathway was discovered in the 1980s to be a central component of the cellular protein-degradation machinery with essential functions in homeostasis, which include preventing the accumulation of misfolded or deleterious proteins. Cancer cells produce proteins that promote both cell survival and proliferation, and/or inhibit mechanisms of cell death. This notion set the stage for preclinical testing of proteasome inhibitors as a means to shift this fine equilibrium towards cell death. Since the late 1990s, clinical trials have been conducted for a variety of malignancies, leading to...
Source: Clinical Lymphoma and Myeloma - January 24, 2017 Category: Cancer & Oncology Authors: Manasanch EE, Orlowski RZ Tags: Nat Rev Clin Oncol Source Type: research

The landscape of new drugs in lymphoma.
Abstract The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhel...
Source: Clinical Lymphoma and Myeloma - December 29, 2016 Category: Cancer & Oncology Authors: Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J, Advani R, Forero A, Morschhauser F, Kersten MJ, Tobinai K, Zinzani PL, Zucca E, Abramson J, Vose J Tags: Nat Rev Clin Oncol Source Type: research

Obesity and Other Cancers.
Conclusion Together, these data add support to the evidence for a growing cancer burden caused by adiposity in both early adult and later adult life, yet leave open the question of the means of weight management after diagnosis as a strategy to improve survival. PMID: 27903157 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 3, 2016 Category: Cancer & Oncology Authors: Yang L, Drake BF, Colditz GA Tags: J Clin Oncol Source Type: research

Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
CONCLUSION: We found patients with CML treated with TKIs had a higher relative incidence of SM compared with the expected incidence among the general Chinese population. However, the correlations between second cancer and the potential risk factors including the length of exposure and cumulative dose of TKIs were not found in this study. PMID: 27397576 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 1, 2016 Category: Cancer & Oncology Authors: Yin XF, Wang JH, Li X, Yu MX, Ma ZX, Jin J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Nonadherent Spheres With Multiple Myeloma Surface Markers Contain Cells that Contribute to Sphere Formation and Are Capable of Internalizing Extracellular Double-Stranded DNA.
CONCLUSION: Nonadherent 3-D cell colonies (spheres) encompass B cells with CD73/CD20(+)/CD45(+)/CD19(dim) phenotype, as well as double-stranded DNA-internalizing cells. The latter cell type appears to function as a sphere-forming center. Different cells in the spheres communicate with each other by secreting specific sets of cytokines. For successful engraftment and tumor growth in mice, intact spheres containing ∼ 10(6) cells must be used. PMID: 27431933 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 1, 2016 Category: Cancer & Oncology Authors: Dolgova EV, Shevela EY, Tyrinova TV, Minkevich AM, Proskurina AS, Potter EA, Orishchenko KE, Zavjalov EL, Bayborodin SI, Nikolin VP, Popova NA, Pronkina NV, Ostanin AA, Chernykh ER, Bogachev SS Tags: Clin Lymphoma Myeloma Leuk Source Type: research

FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Abstract FLT3 (Fms-like tyrosine kinase 3) inhibitors are tyrosine kinase inhibitors. The first-generation FLT3 inhibitors were developed several years ago and include midostaurin, lestaurtinib, sunitinib, and sorafenib. They are relatively nonspecific for FLT3, with other potential targets that include platelet-derived growth factor receptor, vascular endothelial growth factor receptor, KIT, and Janus kinase 2. The second-generation inhibitors, including quizartinib, crenolanib, PLX3397, and ASP2215, are more potent and selective than the first-generation inhibitors. The greater potency and selectivity promises g...
Source: Clinical Lymphoma and Myeloma - October 1, 2016 Category: Cancer & Oncology Authors: Hassanein M, Almahayni MH, Ahmed SO, Gaballa S, El Fakih R Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Polyclonal Localized Light Chain Amyloidosis-A  Distinct Entity?
Polyclonal Localized Light Chain Amyloidosis-A Distinct Entity? Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):588-592 Authors: Ravindran A, Grogg KL, Domaas DA, Go RS PMID: 27600986 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 1, 2016 Category: Cancer & Oncology Authors: Ravindran A, Grogg KL, Domaas DA, Go RS Tags: Clin Lymphoma Myeloma Leuk Source Type: research

The T Cell in Myeloma.
Abstract An active role for the immune system in controlling the malignant plasma cell clone in myeloma has been postulated for many years. The clinical states of monoclonal gammopathy of undetermined significance, plateau phase disease, and smoldering myeloma all suggest that a significant host-tumor interaction is taking place. The fundamental role of the cytotoxic T cell in tumor elimination and control has been exemplified by the dramatic efficacy of adoptive T-cell therapies in many hemopoietic malignancies. However, tumor-host cross-talk results in suppression of the endogenous cytotoxic T-cell response agai...
Source: Clinical Lymphoma and Myeloma - October 1, 2016 Category: Cancer & Oncology Authors: Joshua D, Suen H, Brown R, Bryant C, Ho PJ, Hart D, Gibson J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis.
CONCLUSIONS: CDIH functionally behaves as aggressive NHL despite the fact that under the microscope the lymphomas resemble typical indolent NHLs. These cases seem to fare better when treated with a regimen containing doxorubicin-rituximab. PMID: 27618361 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 1, 2016 Category: Cancer & Oncology Authors: Cabanillas F, Rivera N, Pardo WI Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.
CONCLUSION: These observations demonstrate that the addition of vorinostat to patients with lenalidomide- and dexamethasone-refractory multiple myeloma was associated with moderate response and was well-tolerated, warranting further assessment in a larger prospective study. PMID: 27769558 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 1, 2016 Category: Cancer & Oncology Authors: Bilotti E, Vesole DH, McBride L, Schmidt L, Gao Z, Gilani M, McNeill A, Bednarz U, Richter J, Mato A, Graef T, Siegel DS Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Increased Bone Marrow Iron Scores Are Strongly Correlated With Elevated Serum Ferritin Levels and Poorer Survival in Patients With Iron Overload That Underwent Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experience.
Abstract BACKGROUND: Iron overload is one of the most significant problems as a leading cause of death in patients with leukemia and those who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT). METHODS: In the current study, we retrospectively evaluated the bone marrow iron scores (BMIS) in patients who underwent alloHSCT (n = 125). The first available bone marrow biopsy specimens prior to the alloHSCT procedure or date of hospitalization (control group) were assessed in a blinded fashion using a standardized scoring system. RESULTS: A total of 125 patients were enrolled i...
Source: Clinical Lymphoma and Myeloma - October 1, 2016 Category: Cancer & Oncology Authors: Sivgin S, Nazlim S, Zararsiz G, Baspinar O, Kaynar L, Deniz K, Cetin M, Unal A, Eser B Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Exposure-response analysis to assess the concentration-QTc relationship of CC-122.
Abstract CC-122 hydrochloride is a novel pleiotropic pathway modifier compound that binds cereblon, a substrate receptor of the Cullin 4 RING E3 ubiquitin ligase complex. CC-122 has multiple activities including modulation of immune cells, antiproliferative activity of multiple myeloma and lymphoma cells, and antiangiogenic activity. CC-122 is being developed as an oncology treatment for hematologic malignancies and advanced solid tumors. Cardiovascular and vital sign assessments of CC-122 have been conducted in hERG assays in vitro and in a 28-day good laboratory practice monkey study with negative signals. To as...
Source: Clinical Lymphoma and Myeloma - September 29, 2016 Category: Cancer & Oncology Authors: Li Y, Carayannopoulos LN, Thomas M, Palmisano M, Zhou S Tags: Clin Pharmacol Source Type: research

2016 US lymphoid malignancy statistics by World Health Organization subtypes.
Abstract Collectively, lymphoid neoplasms are the fourth most common cancer and the sixth leading cause of cancer death in the United States. The authors provide contemporary lymphoid neoplasm statistics by subtype based on the 2008 World Health Organization classifications, including the most current US incidence and survival data. Presented for the first time are estimates of the total numbers of US lymphoid neoplasm cases by subtype as well as a detailed evaluation of incidence and survival statistics. In 2016, 136,960 new lymphoid neoplasms are expected. Overall lymphoma incidence rates have declined in recent...
Source: Clinical Lymphoma and Myeloma - September 12, 2016 Category: Cancer & Oncology Authors: Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR Tags: CA Cancer J Clin Source Type: research

Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
HT Abstract Plerixafor in combination with granulocyte-colony stimulating factor (G-CSF) is approved for autologous stem cell mobilization in poor mobilizing patients with multiple myeloma or malignant lymphoma. The purpose of this study was to evaluate efficacy and safety of plerixafor in an immediate rescue approach, administrated subsequently to G-CSF alone or chemotherapy and G-CSF in patients at risk for mobilization failure. Eighty-five patients mobilized with G-CSF alone or chemotherapy were included. Primary endpoint was the efficacy of the immediate rescue approach of plerixafor to achieve ≥2.0 ×...
Source: Clinical Lymphoma and Myeloma - August 31, 2016 Category: Cancer & Oncology Authors: Worel N, Fritsch G, Agis H, Böhm A, Engelich G, Leitner GC, Geissler K, Gleixner K, Kalhs P, Buxhofer-Ausch V, Keil F, Kopetzky G, Mayr V, Rabitsch W, Reisner R, Rosskopf K, Ruckser R, Zoghlami C, Zojer N, Greinix HT Tags: J Clin Apher Source Type: research

Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas.
CONCLUSION: Expression of CD30 in patients with both DLBCL and other aggressive B-cell lymphomas and the absence of MYC oncogene-driven proliferation in the majority of these tumors suggests that brentuximab may be a particularly effective form of targeted therapy in the subset of patients with high CD30 expression. PMID: 27521276 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Malysz J, Erdman P, Klapper J, Zhu J, Creer M, Bayerl MG Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Diversities of Calreticulin Gene Mutations in Macedonian Patients With Essential Thrombocythemia.
CONCLUSION: Our results showed that a wide range of different CALR mutations are associated with a distinct ET clinical phenotype that is associated with the male gender, younger age at diagnosis, higher platelet and lower leukocyte and erythrocyte counts and lower hemoglobin level, and a milder clinical course. The relatively high frequency of new insertion/deletion mutations indicate that the use of fluorescent polymerase chain reaction followed by capillary electrophoresis is the method of choice for the analysis of these defects. PMID: 27521277 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Panovska-Stavridis I, Eftimov A, Ivanovski M, Stojanovic A, Georgievski B, Cevreska L, Dimovski AJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology.
PMID: 27521304 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: List AF, Kantarjian H, Freireich EJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Increased Hepatic Iron Content Predicts Poor Survival in Patients With Iron Overload Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation.
Abstract AIM: Iron overload results in increased infection, venous-oclusive disease and hepatic dysfunction in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. Liver is one of the most common sites of iron overload. PATIENTS AND METHODS: A total of 50 alloHSCT recipients that underwent liver biopsy in Erciyes Stem Cell Transplantation Hospital, Erciyes University, between 2004 and 2011 were enrolled in the study. The liver biopsy specimens have been obtained from the archives of Erciyes University, Department of Pathology and stainned for iron content. RESULTS: The mean age was found ...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Sivgin S, Baldane S, Deniz K, Zararsiz G, Kaynar L, Cetin M, Unal A, Eser B Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Prognosis of Primary Myelofibrosis in the Genomic Era.
Abstract Currently, prognostication in primary myelofibrosis (PMF) relies on the International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS), and DIPSS-plus, which incorporate age, blood counts, constitutional symptoms, circulating blasts, red cell transfusion need, and karyotype. Although the JAK2 V617F mutation was discovered a decade ago and MPL mutations shortly thereafter, it was the recent discovery of CALR mutations in the vast majority of JAK2/MPL-unmutated patients and recognition of the powerful impact of CALR mutations and triple-negative (JAK2/MPL/CALR-negative) status on outcome that set the ...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Bose P, Verstovsek S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

How to Treat Essential Thrombocythemia and Polycythemia Vera.
e;n A Abstract Polycythemia vera and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms associated with thrombotic or hemorrhagic complications, and increased risk of transformation to myelofibrosis and acute myeloid leukemia. The main goal of therapy is aimed at preventing vascular events that are the leading cause of morbidity and mortality in these patients. Accordingly, risk stratification is the basis for deciding when to treat a patient with cytoreductive therapy. The European LeukemiaNet has developed a series of management recommendations for front-line and second-line therapy to provi...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Besses C, Alvarez-Larrán A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
Abstract Myeloproliferative neoplasms (MPN) in chronic phase that evolve into blast phase (BP) hold a dismal prognosis and represent an urgent unmet clinical need. The mutational landscape of MPN-BP is distinct from de novo acute myeloid leukemia and offers insight into molecular mechanisms contributing to clonal evolution providing potential novel drug targets. A number of retrospective studies have identified patient- and disease-specific variables associated with increased risk of leukemic transformation (LT) of an underlying MPN. Several prognostic models have been developed to identify those MPN patients at h...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Mascarenhas J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Clonal Evolution in Multiple Myeloma.
Abstract Multiple myeloma (MM) is the second most common hematologic malignancy encountered among patients in the United States. The last decade has seen incremental improvements in the survival of patients with MM. These advances are, to a large extent, attributable to the addition of proteasome inhibitors and immunomodulatory drugs to the armamentarium of treatment options. The adoption of these drug classes was the result of an empiric research paradigm. However, with the application of next generation sequencing technologies, we are now starting to unravel the genomic landscape of MM. It is hoped that this wil...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Fakhri B, Vij R Tags: Clin Lymphoma Myeloma Leuk Source Type: research

How to Think About Risk in Myeloma.
Abstract An integral part of myeloma therapy is risk stratification of newly diagnosed patients. This method involves a combination of staging and genetic risk assessment. Although survival has dramatically improved for patients with genetically defined, standard-risk myeloma, those with high-risk disease remain a therapeutic challenge. Current treatment approaches might include the use of combination therapy for induction and maintenance. Future approaches are expected to involve drugs that are "risk agnostic," such as monoclonal antibodies and immunotherapy. PMID: 27521310 [PubMed - as supplied by...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Krishnan A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Is Maintenance Therapy for Everyone?
Abstract Although myeloma remains an incurable disease among majority of myeloma patients, the prognosis has significantly improved after the introduction of novel agents. While more agents are being explored for their anti-myeloma activity, the more familiar agents with a better tolerability profile have been tested in the maintenance arena. Lenalidomide and bortezomib so far have shown promise as effective maintenance agents in prolonging PFS, and also OS in some studies. The current review aims at describing the clinical data supporting various maintenance therapies and also at providing some clarity to a few c...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Nooka AK, Lonial S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Successful Nonsurgical Eradication of Invasive Gastric Mucormycosis.
PMID: 27521312 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: El Hachem G, Chamseddine N, Saidy G, Choueiry C, Afif C Tags: Clin Lymphoma Myeloma Leuk Source Type: research

The Prognostic Significance of Elevated Serum Ferritin Levels Prior to Transplantation in Patients With Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation (autoHSCT): Role of Iron Overload.
Abstract INTRODUCTION: Hematopoietic stem cell transplantation is a common and preferred treatment of lymphomas in many centers. Our goal was to determine the association between pretransplant iron overload and survival in patients who underwent autologous hematopoietic stem cell transplantation (autoHSCT). PATIENTS AND METHODS: A total of 165 patients with lymphoma, who underwent autoHSCT between the years of 2007 and 2014, were included in this study. Ferritin levels were used to determine iron status; the cut-off value was 500 ng/mL. The relationship between iron overload and survival was assessed by stati...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Sivgin S, Karamustafaoglu MF, Yildizhan E, Zararsiz G, Kaynar L, Eser B, Cetin M, Unal A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature.
CONCLUSIONS: LYG is a rare B-cell lymphoproliferative disorder with involvement if the respiratory system. The presentation is heterogeneous, and response to therapy is variable. Although it is considered a poor prognosis disease, long-term survivors in remission have been described. PMID: 27521314 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Chavez JC, Sandoval-Sus J, Horna P, Dalia S, Bello C, Chevernick P, Sotomayor EM, Sokol L, Shah B Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Management and Outcomes of HIV-Associated Primary Effusion Lymphoma: A Single Center Experience.
CONCLUSIONS: Given its rarity, our knowledge of PEL relies solely on case reports and case series. Prompt HAART and chemotherapy may be effective in HIV- associated PEL and good outcomes are possible. LDH and CD4 may be possible prognostic factors in PEL. PMID: 27521315 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Gupta A, Sen S, Marley E, Chen W, Naina HV Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma.
CONCLUSION: Detection of cell-free plasma EBV-DNA was highly concordant with the presence of EBERs in tumor tissue, predicted survival independent of LDH and LCT, and should be further studied as a biomarker in AS CTCL. PMID: 27521316 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Haverkos BM, Gru AA, Geyer SM, Bingman AK, Hemminger JA, Mishra A, Wong HK, Pancholi P, Freud AG, Caligiuri MA, Baiocchi RA, Porcu P Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia.
CONCLUSION: There is a significant correlation between some markers, and certain ALL recurrent cytogenetic subgroups (CD123 and hyperdiploidy, CD79b negativity, and ETV-RUNX1 group) have good prognostic value. CD200 can be used as MRD markers in ALL patients and can also can serve as therapy targets. PMID: 27521317 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Adnan Awad S, Kamel MM, Ayoub MA, Kamel AM, Elnoshokaty EH, El Hifnawi N Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States.
We present 10 patients with acute and lymphomatous subtypes of ATLL treated with distinct induction regimens, including CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine [Oncovin], prednisone or prednisolone), interferon/zidovudine, and VCAP-AMP-VECP (vincristine, cyclophosphamide, doxorubicin, prednisone; doxorubicin, ranimustine, prednisone; vindesine, etoposide, carboplatin, prednisone). RESULTS: The overall response rate was 50%, with 10% complete remission (CR). Two patients achieved CR with the second-line regimen. Three patients underwent consolidation with allogeneic stem cell transplantation (ASCT) in ...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Roe C, Komrokji R, Zhang L, Price S, Sokol L Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Bone Marrow Necrosis: An Unusual Initial Presentation of Sickle Cell Anemia.
PMID: 27521319 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: El Hachem G, Chamseddine N Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Abstract Adult patients with acute lymphoblastic leukemia who relapse after frontline therapy have extremely poor outcomes despite advances in chemotherapy and hematopoietic stem cell transplantation. Blinatumomab is a first-in-class bispecific T-cell engager that links T cells to tumor cells leading to T-cell activation and tumor cell lysis. In December 2014, the Food and Drug Administration approved blinatumomab for treatment of relapsed or refractory Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia. In a phase II trial, blinatumomab produced response rates of 43%, and 40% of patien...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Folan SA, Rexwinkle A, Autry J, Bryan JC Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Acute Myeloid Leukemia: Past, Present, and Prospects for the Future.
Abstract Dose intensification of chemotherapy and the combination of a third cytotoxic agent with standard cytarabine and anthracycline-based induction chemotherapy have led to improved outcomes in select groups of patients with acute myeloid leukemia (AML). However, despite some progress in this area, it appears that we might be reaching the limit of cytotoxic chemotherapy for the treatment of AML, especially in older patients and in those with poor-risk features whose disease tends to be relatively chemoresistant. Recent advances in the molecular classification of AML have identified pathogenic pathways that can...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Short NJ, Ravandi F Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes.
Abstract The higher risk myelodysplastic syndrome (MDS) patients, defined by the International Prognostic Scoring System (IPSS) as intermediate-2 or high-risk groups, compromise a third of MDS patients who have an expected survival of less than 1.5 years. Our ability to better define higher risk MDS improved with the proposal of new clinical risk models such as the revised IPSS and by integration of molecular data, including somatic gene mutations. Allogeneic hematopoietic stem-cell transplantation (AHSCT) remains the only curative option. In higher risk MDS patients, proceeding early with AHSCT is associated with...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Komrokji RS Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome.
CONCLUSION: IST has a hematologic improvement response rate in the range of other therapies approved for lower risk MDS. High risk IPSS-R, poor karyotype, and treatment after 2 years from diagnosis have unfavorable response trend. ATG with CSA has higher response than ATG alone. First-line ATG or after lenalidomide had better response trend compared to third-line therapy or azacitidine therapy. PMID: 27521323 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Haider M, Al Ali N, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.
Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative option for patients with myelodysplastic syndrome (MDS). Because MDS predominantly affects an older population, age-associated comorbidities can preclude patients from cure. HSCT is associated with the risk of morbidity and mortality; however, with safer conditioning regimens and improved supportive care, eligible patients with an appropriately matched donor can receive this therapy without exclusion by older age alone. We discuss the role of improved MDS prognostic scoring systems and molecular testing for selection for H...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Mishra A, Anasetti C Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience.
CONCLUSION: MDS is rare and tends to be more aggressive in the AYA population. Karyotype was the most important prognostic factor. Allogeneic stem-cell transplantation offered younger patients the best outcomes. PMID: 27521325 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Grabska J, Shah B, Reed D, Al Ali N, Padron E, Ramadan H, Lancet J, List A, Komrokji R Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Trends in Clinical Investigation for Myelodysplastic Syndromes.
Abstract Myelodysplastic syndrome (MDS) paradigms have been dramatically changed over the last 10 years by major breakthroughs on both pathophysiologic and therapeutic aspects. It is currently a field of intense clinical investigation as new challenges have emerged in both low-risk and high-risk populations. In low-risk MDS, long-term control of anemia is a major issue, and second-line treatments after failure of erythropoiesis-stimulating agents are warranted. Several promising therapies are available, and there are many open questions on how to select the most adapted agent and/or sequence of agents in a specifi...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Prebet T, Zeidan A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Perspectives and Future Directions for Acute Lymphoblastic Leukemia.
PMID: 27521327 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Advani AS Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.
CONCLUSION: Further clinical studies are needed to identify patients with CMML who will benefit from this treatment. PMID: 27521328 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Ramadan H, Duong VH, Al Ali N, Padron E, Zhang L, Lancet JE, List AF, Komrokji RS Tags: Clin Lymphoma Myeloma Leuk Source Type: research

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
CONCLUSION: These results should be confirmed in a larger patient cohort. PDE4 expression could be an effective potential prognostic factor and therapeutic target for patients with MDS and chronic myelomonocytic leukemia. The role of PDE4 inhibitors should be explored in vitro against MDS cell lines and in preclinical mouse models of MDS. PMID: 27521329 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Chamseddine AN, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Bohannan ZS, Garcia-Manero G Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Abstract The treatment of patients with chronic lymphocytic leukemia (CLL) whose tumor presents the del(17p)/TP53 mutation is a major challenge. Treatment with chemo(immuno)therapy, immunomodulators, or the anti-CD52 monoclonal antibody alemtuzumab produces transient, unsatisfactory responses. Reduced-intensity-conditioning allotransplantation produces sustained progression-free survival and overall survival (40%-60% at 5 years), equivalent to the cure of the disease, even in cases with adverse biomarkers. Unfortunately, despite improvements in this procedure, the non-relapse mortality continues to be high (15%-30...
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Montserrat E, Dreger P Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
We present the trends of their disease evolution. RESULTS: The median of age at diagnosis was 42 years. Within a year, 19 (22%) of 86 patients developed imatinib intolerance, all of them with grade III or IV disease that required imatinib dose reduction or discontinuation. Of these patients, 16 (84%) of 19 developed transformation to blastic phase. The cumulative incidences of blastic phase development were 47% in the nonintolerant group and 84% in the intolerant group. There was a relative risk for those with imatinib intolerance to develop blastic phase of 1.78 (95% confidence interval, 1.28 to 2.42) (P 
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Ángeles-Velázquez JL, Hurtado-Monroy R, Vargas-Viveros P, Carrillo-Muñoz S, Candelaria-Hernández M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.
CONCLUSION: These findings suggest that dasatinib therapy (within the therapeutic range) can increase trabecular bone, without causing significant changes in bone and mineral metabolism. Nonetheless, monitoring of bone health and skeletal integrity should be included into the long-term management of patients treated with dasatinib to further enhance our understanding of its safety profile and its potential role as a treatment modality for other bone diseases. PMID: 27521332 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Hoehn D, Cortes JE, Medeiros LJ, Jabbour EJ, Hidalgo JE, Kanagal-Shamanna R, Bueso-Ramos CE Tags: Clin Lymphoma Myeloma Leuk Source Type: research

When to Consider Allogeneic Transplantation in CML.
Abstract Tyrosine kinase inhibitor (TKI) therapy has radically altered the treatment strategy for chronic myeloid leukemia. Allogeneic transplantation, which over a decade ago was considered the definitive therapy for CML, is now appropriately used in cases where all TKIs are not tolerated, in cases of resistance to TKI therapy, or when the disease progresses from chronic phase to accelerated or blast phase. PMID: 27521333 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2016 Category: Cancer & Oncology Authors: Radich J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Peripheral blood stem cells collection on spectra optia apheresis system using the continuous mononuclear cell collection protocol: A single center report of 39 procedures.
CONCLUSIONS: Spectra Optia CMNC protocol successfully collected CD34+ cells with yields permitting the harvest of sufficient enriched grafts for autologous transplantation. The CD34+ cell yield prediction was excellent. PBSC collection with CMNC protocol had advantages of high processing rate, low product volume, and acceptable contamination by platelets. PMID: 27442837 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 21, 2016 Category: Cancer & Oncology Authors: Sanderson F, Poullin P, Smith R, Nicolino-Brunet C, Philip P, Chaib A, Costello R Tags: J Clin Apher Source Type: research